SI-BONE Announces Voluntary Recall of iFuse TORQ Implants
TipRanks (Fri, 11-Sep 4:33 PM ET)
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
Globe Newswire (Mon, 31-Aug 4:09 PM ET)
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
Globe Newswire (Mon, 3-Aug 4:09 PM ET)
SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026
Globe Newswire (Mon, 20-Jul 4:09 PM ET)
Globe Newswire (Tue, 14-Jul 3:30 AM ET)
Market Chameleon (Tue, 12-May 6:37 AM ET)
SI-BONE Projects 20% Revenue Growth in 2025—Physician Base and Cash Reserves Also Expand
Market Chameleon (Mon, 12-Jan 4:39 AM ET)
SIBN Lifts 2025 Outlook After Delivering 21% Revenue Growth and Positive Cash Flow
Market Chameleon (Tue, 11-Nov 6:15 AM ET)
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Si-Bone trades on the NASDAQ stock market under the symbol SIBN.
As of September 11, 2026, SIBN stock price climbed to $18.38 with 546,425 million shares trading.
SIBN has a beta of 0.25, meaning it tends to be less sensitive to market movements. SIBN has a correlation of 0.00 to the broad based SPY ETF.
SIBN has a market cap of $815.14 million. This is considered a Small Cap stock.
Last quarter Si-Bone reported $56 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $761,272 and exceeded earnings estimates by $.06.
In the last 3 years, SIBN traded as high as $23.25 and as low as $11.48.
The top ETF exchange traded funds that SIBN belongs to (by Net Assets): VTI, VXF, VTWO, SCHA, DFAS.
SIBN has underperformed the market in the last year with a price return of +17.4% while the SPY ETF gained +18.3%. However, in the short term, SIBN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +19.6% vs +5.6% return in SPY. But in the last 2 weeks, SIBN shares have been beat by the market, returning -4.3% compared to an SPY return of -0.9%.
SIBN support price is $17.88 and resistance is $18.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SIBN shares will trade within this expected range on the day.